Screener
Krystal Biotech, Inc. KRYS United States — Product revenue, net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
FAQ
- What is Krystal Biotech, Inc.'s united states — product revenue, net?
- Krystal Biotech, Inc. (KRYS) reported united states — product revenue, net of $87.49M in Q1 2026.
- What does united states — product revenue, net mean?
- This metric represents the total net revenue generated from the sale of pharmaceutical products within the United States market, after accounting for returns, allowances, and rebates. It serves as a primary indicator of the commercial adoption and market penetration of the company's gene therapy portfolio in its domestic region. This figure is critical for assessing the scalability of the company's proprietary platform and the effectiveness of its commercialization strategy in the rare disease space.
Ask your AI about Krystal Biotech, Inc.'s united states — product revenue, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude